Clinical Trial Update: Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, efficacy, and tolerability of PF-06480605 in moderate to severe ulcerative colitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• PF-06480605

Snippet

Sponsor: Telavant, Inc. | Conditions: Colitis, Ulcerative | Phase 2 | Status: COMPLETED | Results posted: 2019-06-19